ImmunityBio (IBRX) Gross Profit (2023 - 2026)

ImmunityBio (IBRX) has 4 years of Gross Profit data on file, last reported at $44.0 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 167.14% year-over-year to $44.0 million in Q1 2026; TTM through Mar 2026 was $140.0 million, a 349.38% increase from a year earlier, with the FY2025 full-year figure at $112.5 million, up 663.21% from the prior year.
• Gross Profit for Q1 2026 stood at $44.0 million, up from $37.9 million in the prior quarter.
• Over the last five years, Gross Profit for IBRX reached as high as $44.0 million in Q1 2026 and fell as low as $40000.0 in Q1 2024.
• Historically, Gross Profit has averaged $14.3 million across 4 years, with a median of $6.8 million in 2024.
• Across the five-year window, Gross Profit soared 41047.5% in 2025 and soared 167.14% in 2026, its largest moves.
• Year by year, Gross Profit stood at $139000.0 in 2023, then soared by 5333.09% to $7.6 million in 2024, then soared by 401.89% to $37.9 million in 2025, then advanced by 16.0% to $44.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $44.0 million in Q1 2026, $37.9 million in Q4 2025, and $31.9 million in Q3 2025.